Truist Securities Reiterates Buy on PROCEPT BioRobotics, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on PROCEPT BioRobotics and increased the price target from $95 to $105.
October 30, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on PROCEPT BioRobotics and increased the price target from $95 to $105, indicating confidence in the company's future performance.
The reiteration of a Buy rating and an increased price target by Truist Securities suggests positive sentiment and expected growth for PROCEPT BioRobotics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100